<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529126</url>
  </required_header>
  <id_info>
    <org_study_id>SKY0402C209</org_study_id>
    <nct_id>NCT00529126</nct_id>
  </id_info>
  <brief_title>Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 study to evaluate three dose levels of SKY0402 compared with 75 mg of bupivacaine&#xD;
      HCl.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effective postoperative pain control is a critical element in patient recovery, as the&#xD;
      majority of patients may experience significant pain, particularly in the first few days&#xD;
      following surgery. Appropriate postoperative pain management contributes to improved healing,&#xD;
      faster patient mobilization, shortened hospital stays, and reduced healthcare costs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours</measure>
    <time_frame>0 to 72 hours</time_frame>
    <description>To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question: &quot;On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>SKY0402 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKY0402, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKY0402 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKY0402, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKY0402 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKY0402, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine HCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKY0402</intervention_name>
    <description>SKY0402</description>
    <arm_group_label>SKY0402 high dose</arm_group_label>
    <arm_group_label>SKY0402 low dose</arm_group_label>
    <arm_group_label>SKY0402 middle dose</arm_group_label>
    <other_name>EXPAREL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>Bupivacaine HCl</description>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <other_name>Marcaine 0.25% with epinephrine 1:200,000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 18 years of age and older at the Screening Visit.&#xD;
&#xD;
          2. Applies to female subjects only: Postmenopausal, surgically sterile, or willing to use&#xD;
             acceptable means of contraception for at least 30 days after surgery including any of&#xD;
             the following: hormonal contraceptives (e.g., oral, injectable, implantable starting&#xD;
             at least 30 days before study drug administration), effective double-barrier methods&#xD;
             (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice&#xD;
             of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a&#xD;
             partner who has had a vasectomy.&#xD;
&#xD;
          3. Scheduled to undergo 2- or 3-column excisional hemorrhoidectomy under general&#xD;
             anesthesia using Milligan Morgan or Ferguson-type techniques, including modified&#xD;
             approaches with specialized instruments, such as LigaSureâ„¢ or harmonic scalpel, with a&#xD;
             cumulative incision length of a minimum 3 cm.&#xD;
&#xD;
          4. American Society of Anesthesiology (ASA) Physical Class 1-3.&#xD;
&#xD;
          5. Able and willing to comply with all study visits and procedures.&#xD;
&#xD;
          6. Able to speak, read, and understand the language of the Informed Consent Form (ICF),&#xD;
             study questionnaires, and other instruments used for collecting subject-reported&#xD;
             outcomes, in order to enable accurate and appropriate responses to pain scales and&#xD;
             other required study assessments.&#xD;
&#xD;
          7. Willing and capable of providing written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy, nursing, or planning to become pregnant during the study or within one&#xD;
             month after study drug administration.&#xD;
&#xD;
          2. Use of any of the following medications within the times specified before surgery:&#xD;
&#xD;
               -  Long-acting opioid medication within 3 days.&#xD;
&#xD;
               -  Any opioid medication within 24 hours.&#xD;
&#xD;
          3. Concurrent painful physical condition that may require analgesic treatment in the&#xD;
             postoperative period for pain that is not surgically related and may confound the&#xD;
             postoperative assessments (e.g., rheumatoid arthritis, chronic neuropathic pain).&#xD;
&#xD;
          4. Single-column hemorrhoidectomy or hemorrhoidectomy without an internal component.&#xD;
&#xD;
          5. Body weight less than 50 kilograms (110 pounds).&#xD;
&#xD;
          6. History of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics&#xD;
             or to opioid medication.&#xD;
&#xD;
          7. Contraindication to epinephrine, such as concurrent administration of monoamine&#xD;
             oxidase (MAO) inhibitors or antidepressants of amitriptyline or imipramine types,&#xD;
             conditions where the production or exacerbation of tachycardia could prove fatal&#xD;
             (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other&#xD;
             pathological conditions that might be aggravated by the effects of epinephrine.&#xD;
&#xD;
          8. Contraindications to any of the pain-control agents planned for postoperative use&#xD;
             (e.g., acetaminophen [paracetamol], oxycodone, morphine, ketorolac).&#xD;
&#xD;
          9. Administration of an investigational drug within 30 days or 5 elimination half-lives&#xD;
             of such investigational drug, whichever is longer, prior to study drug administration,&#xD;
             or planned administration of another investigational product or procedure during the&#xD;
             subject's participation in this study.&#xD;
&#xD;
         10. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription&#xD;
             medicine(s), or alcohol within the past 2 years.&#xD;
&#xD;
         11. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the&#xD;
             opinion of the Investigator, may interfere with study assessments or compliance.&#xD;
&#xD;
         12. Significant medical conditions or laboratory results that, in the opinion of the&#xD;
             Investigator, indicate an increased vulnerability to study drugs and procedures, and&#xD;
             expose the subject to an unreasonable risk as a result of participating in this&#xD;
             clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial&#xD;
             or complete conduction block, impaired cardiac function, untreated hypertension,&#xD;
             advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing&#xD;
             abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis),&#xD;
             advanced liver disease, severe renal impairment, advanced diabetes, comorbid&#xD;
             conditions associated with an immunocompromised status, such as blood dyscrasias,&#xD;
             HIV/AIDS, or recent chemotherapy.&#xD;
&#xD;
             In addition, the subject will be ineligible to receive study drug if he or she meets&#xD;
             the following criteria during surgery:&#xD;
&#xD;
         13. Any clinically significant event or condition uncovered during the surgery (e.g.,&#xD;
             excessive bleeding, acute sepsis) that might render the subject medically unstable or&#xD;
             complicate the subject's postoperative course.&#xD;
&#xD;
         14. A cumulative incision length less than 3 cm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erol Onel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accurate Clinical Trials, Inc.</name>
      <address>
        <city>San Clemente</city>
        <state>California</state>
        <zip>92673</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami/Jackson Memorial</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Women's Hospital of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare Health Systems Laboratories</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC Imereti Regional Clinical Hospital of the Name A. Dzotsenidze</name>
      <address>
        <city>Kutaisi</city>
        <zip>4600</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC K. Eristavi National Center of Experimental and Clinical Surgery</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Socieety with limited responsibility Proctology Center</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <results_first_submitted>November 23, 2011</results_first_submitted>
  <results_first_submitted_qc>July 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2013</results_first_posted>
  <disposition_first_submitted>August 25, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 1, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 6, 2010</disposition_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemorrhoidectomy</keyword>
  <keyword>pain</keyword>
  <keyword>Postoperative</keyword>
  <keyword>analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SKY0402 High Dose (300mg)</title>
          <description>SKY0402 300mg single dose administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="P2">
          <title>SKY0402 Middle Dose (225mg)</title>
          <description>A single dose 225mg SKY0402 administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="P3">
          <title>SKY0402 Low Dose (75mg)</title>
          <description>A single dose 75mg SKY0402 administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="P4">
          <title>Bupivacaine HCl 75mg</title>
          <description>A single dose of 75 mg bupivacaine administered intraoperatively via local infiltration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SKY0402 High Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="B2">
          <title>SKY0402 Middle Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="B3">
          <title>SKY0402 Low Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="B4">
          <title>Bupivacaine HCl</title>
          <description>A single dose of 75 mg bupivacaine was to be administered intraoperatively via local infiltration</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="11.3"/>
                    <measurement group_id="B2" value="41.7" spread="11.2"/>
                    <measurement group_id="B3" value="42.2" spread="11.5"/>
                    <measurement group_id="B4" value="44.2" spread="10.6"/>
                    <measurement group_id="B5" value="43.4" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours</title>
        <description>To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question: &quot;On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?&quot;</description>
        <time_frame>0 to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SKY0402 300mg</title>
            <description>A single dose of SKY0402 300mg administered intraoperatively via local infiltration.</description>
          </group>
          <group group_id="O2">
            <title>SKY0402 225mg</title>
            <description>A single dose of SKY0402 225mg administered intraoperatively via local infiltration.</description>
          </group>
          <group group_id="O3">
            <title>SKY0402 75mg</title>
            <description>A single dose of SKY0402 75mg administered intraoperatively via local infiltration.</description>
          </group>
          <group group_id="O4">
            <title>Bupivacaine HCl</title>
            <description>A single dose of 75 mg bupivacaine was to be administered intraoperatively via local infiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours</title>
          <description>To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question: &quot;On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?&quot;</description>
          <units>units on a scale*hrs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175" spread="173"/>
                    <measurement group_id="O2" value="172" spread="146"/>
                    <measurement group_id="O3" value="225" spread="185"/>
                    <measurement group_id="O4" value="331" spread="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days</title>
        <time_frame>Up to 30 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SKY0402 High Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="E2">
          <title>SKY0402 Middle Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="E3">
          <title>SKY0402 Low Dose</title>
          <description>A single dose of study drug was to be administered intraoperatively via local infiltration.</description>
        </group>
        <group group_id="E4">
          <title>Bupivacaine HCl</title>
          <description>A single dose of 75 mg bupivacaine was to be administered intraoperatively via local infiltration</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Medical Director</name_or_title>
      <organization>Pacira Pharmaceuticals, Inc.</organization>
      <phone>203-837-6500</phone>
      <email>ErolOnel@pacira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

